Oliver C Lomas1,2,3, Sabrin Tahri1,2,3, Irene M Ghobrial1,2,3. 1. Dana-Farber Cancer Institute, Boston. 2. Harvard Medical School, Boston. 3. The Broad Institute, Cambridge, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The aim of the review is to describe recent advances in our understanding of how multiple myeloma interacts with its cellular and molecular neighbours in the bone marrow microenvironment, and how this may provide targets for prognostication and prevention. RECENT FINDINGS: The bone marrow microenvironment in myeloma is beginning to yield targets that are amenable to therapy. A number of trials demonstrate some clinical efficacy in heavily pretreated disease. The challenge remains for how and when these therapeutic interventions are of particular benefit early in disease progression. SUMMARY: Multiple myeloma is rarely curable and its interactions with the bone marrow microenvironment are evident. However, separating cause from effect remains a challenge. We propose that targeting specific niches within the bone marrow will yield therapies that have the potential for significant benefit in myeloma and may facilitate earlier intervention to disrupt an environment that is permissive for myeloma progression.
PURPOSE OF REVIEW: The aim of the review is to describe recent advances in our understanding of how multiple myeloma interacts with its cellular and molecular neighbours in the bone marrow microenvironment, and how this may provide targets for prognostication and prevention. RECENT FINDINGS: The bone marrow microenvironment in myeloma is beginning to yield targets that are amenable to therapy. A number of trials demonstrate some clinical efficacy in heavily pretreated disease. The challenge remains for how and when these therapeutic interventions are of particular benefit early in disease progression. SUMMARY:Multiple myeloma is rarely curable and its interactions with the bone marrow microenvironment are evident. However, separating cause from effect remains a challenge. We propose that targeting specific niches within the bone marrow will yield therapies that have the potential for significant benefit in myeloma and may facilitate earlier intervention to disrupt an environment that is permissive for myeloma progression.
Authors: Madelon M E de Jong; Zoltán Kellermayer; Natalie Papazian; Sabrin Tahri; Davine Hofste Op Bruinink; Remco Hoogenboezem; Mathijs A Sanders; Pieter C van de Woestijne; P Koen Bos; Cyrus Khandanpour; Jessica Vermeulen; Philippe Moreau; Mark van Duin; Annemiek Broijl; Pieter Sonneveld; Tom Cupedo Journal: Nat Immunol Date: 2021-05-20 Impact factor: 25.606
Authors: Douglas E Joshua; Slavica Vuckovic; James Favaloro; Ka Hei Aleks Lau; Shihong Yang; Christian E Bryant; John Gibson; Phoebe Joy Ho Journal: Front Immunol Date: 2021-02-23 Impact factor: 7.561
Authors: Hayley M Sabol; Adam J Ferrari; Manish Adhikari; Tânia Amorim; Kevin McAndrews; Judith Anderson; Michele Vigolo; Rajwinder Lehal; Meloney Cregor; Sharmin Khan; Pedro L Cuevas; Jill A Helms; Noriyoshi Kurihara; Venkat Srinivasan; Frank H Ebetino; Robert K Boeckman; G David Roodman; Teresita Bellido; Jesus Delgado-Calle Journal: Cancer Res Date: 2021-08-04 Impact factor: 12.701
Authors: Esperanza M Algarín; Dalia Quwaider; Francisco J Campos-Laborie; Andrea Díaz-Tejedor; Pedro Mogollón; Elena Vuelta; Montserrat Martín-Sánchez; Laura San-Segundo; Lorena González-Méndez; Norma C Gutiérrez; Ramón García-Sanz; Teresa Paíno; Javier De Las Rivas; Enrique M Ocio; Mercedes Garayoa Journal: Cells Date: 2021-03-04 Impact factor: 6.600